Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Sysmex America
| Company | Sysmex America |
|---|---|
| Name of urinalysis instrument | UN-Series Automated Urinalysis Solution (UN-2000, UN-3000, UN-9000) |
| Contact | Pinak Patel |
| City, State | Lincolnshire, IL |
| Phone | 888-879-7639 |
| Website | |
| Type of instrument | urine chemistry and microscopy/sediment combined |
| Instrument list price | based on configuration (avail. via purchase or lease) |
| First year instrument sold in the U.S. | UN-2000: 2019; UN-3000 and UN-9000: 2020 |
| Approximate No. of units in clinical use in the U.S./outside the U.S. | >600/— (in Canada) |
| Foreign countries where company markets instrument | Canada |
| Country where instrument is designed/manufactured | Japan/Japan |
| Human languages (other than English) supported | — |
| Intended urine sample volume per day | >80 |
| Dimensions (H×W×D) | varies based on configuration |
| Weight fully loaded with reagents/without reagents | both vary based on configuration |
| Power requirements | varies based on configuration |
| Mean time between failure of instrument | 90 days |
| Events that cause instrument to lock or stop analysis | user ID failure, consumables replacement/expiration |
| • Urine chemistry tests available on instrument in the U.S. | bilirubin (0.5–2.7 mg/dL), red blood cells (trace levels), hemoglobin (0.013–0.3 mg/dL), glucose (36–820 mg/dL), ketone (3.6–156 mg/dL), leukocyte esterase (6–91 cells/µL), nitrite (positive/negative), pH (5.3–8.7), protein (10.8–1,000 mg/dL), specific gravity (1.000–1.099), urobilinogen (0.24–6.24 mg/dL) |
| • Color compensation pad included/Flagging thresholds customizable | yes/yes |
| • Test strip configuration | cartridge |
| • Calibration required after each test strip lot No. change | yes |
| • Frequency of customer-performed calibration/Form of calibration | with every new lot No. of Novus cassette loaded or same lot No. loaded and calibration is > 24 hours old/liquid |
| • How results are displayed for urine chemistry | semiquantitative |
| • Specific gravity correction for protein/glucose | no/no |
| • Microscopy/sediment technology | flow cytometry with fluorescent stain |
| • Microscopy/sediment analysis parameters | flagged and qualitative: pathological casts, crystals, yeast-like cells, mucus, sperm; qualitative and quantitative: RBCs; quantitative: WBCs, epithelial cells, bacteria, casts |
| • Flagging thresholds customizable | yes |
| • Instrument eliminates amorphous crystal interference before sample analysis | yes |
| • How results are displayed for microscopy/sediment | numeric values or scattergrams |
| • Reporting format customizable | yes |
| • No. of results that can be held in internal memory | 100,000 sample results (in the urinalysis data manager)/ 2 concentrations × 3 lots (120 plots/lot) for control results |
| Reagent shelf life/storage temp. for unopened containers of calibrator | — |
| Reagent shelf life/storage temp. for opened containers of calibrator | — |
| Reagent shelf life/storage temp. for unopened containers of control reagent | —/2–8°C |
| Reagent shelf life/storage temp. for opened containers of control reagent | — |
| Reagent barcode-reading capability | yes, for all tests (can read Code 39, Code 128, more) |
| How often quality control samples are run | daily |
| Sample throughput per hour/Time to first result for chemistry | 240/— |
| Sample throughput per hour/Time to first result for microscopy/sediment | varies based on configuration/— |
| Analyzer has stat mode | yes (min. sample vol., 1.6 mL for microscopy/sediment) |
| FDA approved for body fluid analysis | no |
| Sample dilutions required for urinalysis/body fluid analysis | no/not applicable |
| Minimum width of sample tube/Minimum length of sample tube | 16 mm/95 mm |
| Conditions or substances that prevent a sample from being run | — |
| Means of sample ID entry | barcode scan, manual entry, worklist download from host, RFID for authentic entry of cassette lot |
| Built-in liquid-level sensing for samples | yes |
| Information that can be barcode scanned on instrument | operator identifier, specimen identifier, reagent lot No. |
| Compatible with laboratory automation systems | yes (Siemens Aptio, Abbott Accelerator a3600) |
| How LOINC codes for results are made available | website, e-mail query |
| Software includes reflex testing/cross-check functionality | yes/yes |
| Instrument automatically generates consolidated report* | yes |
| Instrument archives patient data | yes (patient demographics, test results, sample ID) |
| Instrument connections to transfer information | data-management system that connects to LIS or EHR, or directly to LIS or EHR |
| Interface standards or formats supported | ASTM 1394-91, ASTM 1381, HL7 version 3 |
| Bidirectional interface | yes, to other companies’ LISs and EHRs |
| Test results can be transmitted to LIS as soon as tests completed | yes |
| Connection to LIS/EHR to upload patient and QC results | LIS and EHR: hospital network |
| Information included in transmission to data-management system | device unique identifier, operator ID, patient ID, specimen ID, result, QC identifier |
| Training included with instrument purchase | yes (7 hours of virtual instructor-led training at customer site) |
| Approximate scheduled maintenance time required | 20 min. daily; 10 min. weekly (maintenance records kept onboard instrument) |
| Onboard diagnostics for troubleshooting | yes (can perform diagnostics via remote access) |
| Provide list of client sites to potential customers on request | yes (partial list of comparable sites with no restrictions regarding its use) |
| Clients restricted from sharing their experience with company or software | no |
| Distinguishing instrument features (supplied by company) | combines urine chemistry, fluorescence flow cytometry, and digital image analysis for rapid urine screening; BeyondCare quality monitor for urinalysis provides a streamlined and automated QC experience |
| *chemistry and microscopy results in one report; Note: a dash in lieu of an answer means company did not answer; question or question is not applicable | †modular systems: UN-2000, two modules; UN-3000, three modules; UN-9000, four or more modules |